ALLO

NASD Allogene Therapeutics, Inc.
Oct 2, 2026 · 9:30 PM ET EOD Market Closed

$1.50 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.50, $0.08 below the day’s high of $1.58

YTD change
+9.49%
vs 20-day SMA
-12.97%
vs 200-day SMA
-24.75%

Price ranges

Previous day
$1.53 $1.61
open $1.60 close $1.54
-$0.06 (-3.75%)
Today
$1.50 $1.58
open $1.57 now $1.50
-$0.07 (-4.46%)
Past week
$1.53 $1.70
from $1.67 now $1.50
-$0.17 (-10.18%)
Past month
$1.53 $2.01
from $1.98 now $1.50
-$0.48 (-24.24%)
This year
$1.31 $4.46
from $1.37 now $1.50
+$0.13 (+9.49%)

Price & Performance

-0.98 (-39.52%) / 6M

$1.38$1.98$2.58$3.18Apr 2Jul 6Oct 2

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 97.3% away from all-time highs of $55.00
  • ALLO is up 9% since the beginning of the year
  • ALLO is up 16% over the past 12 months
  • ALLO is down 24% over the past 1 month
  • 20% of all ALLO investors are betting against ALLO

ALLO reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +16.3%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.13
Earnings momentum +11.3% Quarterly EPS growth
Quarterly change +11.3%

Valuation

P/E ratio N/A
Enterprise value $253.0M
Beta 0.70

Balance sheet & scale

IncomeN/A
Revenue$4.6M
Cash$332.6M
Debt$79.0K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $518.2M

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $403.04 -1.04%
MRNA Moderna, Inc. $190.01 +0.57%
RVMD Revolution Medicines, Inc. $206.64 +0.36%
ROIV Roivant Sciences Ltd. $35.72 +0.62%
BNTX BioNTech SE Sponsored ADR $96.90 +0.05%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.